The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesIHC-P: Use at a concentration of 1-5 µg/ml.
WB: Use at a concentration of 1 - 5 µg/ml.
This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionThe reaction catalyzed by topoisomerases leads to the conversion of one topological isomer of DNA to another.
Involvement in diseaseNote=A chromosomal aberration involving TOP1 is found in a form of therapy-related myelodysplastic syndrome. Translocation t(11;20)(p15;q11) with NUP98.
Sequence similaritiesBelongs to the eukaryotic type I topoisomerase family.
Post-translational modificationsSumoylated. Lys-117 is the main site of sumoylation. Sumoylation plays a role in partitioning TOP1 between nucleoli and nucleoplasm. Levels are dramatically increased on camptothecin (CPT) treatment.
Cellular localizationNucleus > nucleolus. Nucleus > nucleoplasm. Diffuse nuclear localization with some enrichment in nucleoli. On CPT treatment, cleared from nucleoli into nucleoplasm. Sumolyated forms found in both nucleoplasm and nucleoli.